Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Mir, Olivier ^a   Coriat, Romain ^a   Blanchet, Benoit ^a   Durand, Jean Philippe ^a   Boudou Rouquette, Pascaline ^a   Michels, Judith ^a   Ropert, Stanislas ^a   Vidal, Michel ^a   Pol, Stanislas ^b   Chaussade, Stanislas ^a   Goldwasser, François ^a  

^a Université Paris Descartes Sorbonne Paris Cité ^*  (France)

^b INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MALE; MUSCLE ATROPHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; LIVER TUMOR; METABOLISM; MIDDLE AGED; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES; SARCOPENIA; SURVIVAL ANALYSIS;

EID: 84861586424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037563     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
3. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, et al. (2010) Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39: 412-423.
6. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12: 489-495.
7. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB, (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21: 1594-1598.
8. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, et al. (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9: 629-635.
9. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15: 2920-2926.
10. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, et al. (2010) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67: 93-101.
11. Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, et al. (2011) Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs DOI 10.1007/s10637-10011-19760-z.
12. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, et al. (2012) Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma. Oncology 82: 119-125.
13. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, et al. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815.
14. Heymsfield SB, Wang Z, Baumgartner RN, Ross R, (1997) Human body composition: advances in models and methods. Annu Rev Nutr 17: 527-558.
15. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, et al. (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85: 115-122.
16. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, et al. (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33: 997-1006.
17. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, et al. (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97: 2333-2338.
18. Blanchet B, Billemont B, Cramard J, Benichou AS, Chhun S, et al. (2009) Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 49: 1109-1114.
19. Meza-Junco J, Montano-Loza A, Prado CMM, Lieffers JR, Baracos VE, et al. (2011) Sarcopenia in patients (pts) with hepatocelluar carcinoma (HCC). J Clin Oncol 29: e14570.
20. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437.
21. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, et al. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27: 1800-1805.
22. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, et al. (2006) Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr 96: 895-901.
23. Kacevska M, Robertson GR, Clarke SJ, Liddle C, (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 4: 137-149.